Get started
Author

Julia Rasmussen

ORCID: 0000-0003-1260-5624
Observed ORCID: 0000-0003-1260-5624
OpenAlex ID: A5078940541
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
2019 · Andrew J. Armstrong, Susan Halabi, et al. · Journal of Clinical Oncology · 364
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer
2021 · Daniel J. George, Susan Halabi, et al. · Cancer · 43
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
2020 · Rhonda L. Bitting, Patrick Healy, et al. · European Urology Oncology · 31
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
2019 · Daniel J. George, Susan Halabi, et al. · Urologic Oncology Seminars and Original Investigations · 30
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer
2017 · Sundhar Ramalingam, Michael S. Humeniuk, et al. · Urologic Oncology Seminars and Original Investigations · 27
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
2024 · Daniel J. George, Susan Halabi, et al. · Journal of Clinical Oncology · 4
PDF
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
2023 · Daniel J. George, Susan Halabi, et al. · Journal of Clinical Oncology · 4
Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
2026 · Andrew J. Armstrong, Lauren Howard, et al. · Journal of Clinical Oncology · 3
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
2024 · Tian Zhang, Lauren Howard, et al. · European Urology Oncology · 2
Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.
2019 · Andrew J. Armstrong, Rhonda L. Bitting, et al. · Journal of Clinical Oncology · 2
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
2023 · Tian Zhang, Lauren Howard, et al. · Journal of Clinical Oncology · 1
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
2019 · Tian Zhang, Bridget F. Koontz, et al. · Journal of Clinical Oncology · 1
Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
2026 · Robert Bruce Montgomery, Lauren Howard, et al. · Journal of Clinical Oncology
PDF
Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).
2025 · Patrick O'Shea, Matthew Labriola, et al. · Journal of Clinical Oncology
PDF
Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
2025 · Daniel J. George, Lauren Howard, et al. · Journal of Clinical Oncology
Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.
2025 · Jennifer A. Freedman, Sean Piwarski, et al. · Journal of Clinical Oncology
PDF
Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.
2025 · Elahe A. Mostaghel, Jennifer A. Freedman, et al. · Journal of Clinical Oncology
PDF
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
2021 · Tian Zhang, Bridget F. Koontz, et al. · Journal of Clinical Oncology
PSA response in black and white patients treated with abiraterone acetate (AA) for metastatic castrate-resistant prostate cancer (mCRPC).
2016 · Sundhar Ramalingam, Michael Sandon Humeniuk, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 512
H-index: 5
I10-index: 5
Year
Topic
Type